NEA puts more money behind novel Parkinson's pill

Brenig Therapeutics, a neurology-focused drug development company using an AI-based discovery platform, has closed a $65 million series A financing.

The funding round was led by New Enterprise Associates (NEA), with participation also from existing investors, including OrbiMed, Torrey Pines Investments, and BioGeneration Ventures.

Based in Delaware, USA, Brenig utilizes a machine learning approach through a partnership with Expert Systems, a drug accelerator that has developed multiple best-in-class clinical candidates across various therapeutic areas.